Translation of an experimental oral vaccine formulation into a commercial product.

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

An effective experimental vaccine may fail to become a therapeutic reality for a number of scientific, regulatory or commercial reasons. In this review, we share some of our personal experiences as University-based researchers and provide an account of some of the problems that we have encountered during preliminary scale-up and assessment of an oral influenza vaccine formulation. Many of the problems we have faced have been non-scientific and related to identifying project-funding sources, finding suitable contract manufacturing companies that are GMP compliant, and protecting intellectual property generated from the scientific studies. The review is intended as a practical guide that will allow other researchers to adopt effective strategies to permit the translation of an effective experimental formulation to a viable commercial product.
Original languageEnglish
Title of host publicationMethods.
Pages65-68
Number of pages4
Volume38
Publication statusPublished - 2006

Fingerprint

Vaccines
Research Personnel
Intellectual Property
Influenza Vaccines
Contracts
Therapeutics

Keywords

  • vaccines

Cite this

@inbook{8147d20d9ece470fa39684d735f60f47,
title = "Translation of an experimental oral vaccine formulation into a commercial product.",
abstract = "An effective experimental vaccine may fail to become a therapeutic reality for a number of scientific, regulatory or commercial reasons. In this review, we share some of our personal experiences as University-based researchers and provide an account of some of the problems that we have encountered during preliminary scale-up and assessment of an oral influenza vaccine formulation. Many of the problems we have faced have been non-scientific and related to identifying project-funding sources, finding suitable contract manufacturing companies that are GMP compliant, and protecting intellectual property generated from the scientific studies. The review is intended as a practical guide that will allow other researchers to adopt effective strategies to permit the translation of an effective experimental formulation to a viable commercial product.",
keywords = "vaccines",
author = "Katharine Carter and Valerie Ferro and James Alexander and Alexander Mullen",
year = "2006",
language = "English",
volume = "38",
pages = "65--68",
booktitle = "Methods.",

}

Translation of an experimental oral vaccine formulation into a commercial product. / Carter, Katharine; Ferro, Valerie; Alexander , James ; Mullen, Alexander.

Methods.. Vol. 38 2006. p. 65-68.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Translation of an experimental oral vaccine formulation into a commercial product.

AU - Carter, Katharine

AU - Ferro, Valerie

AU - Alexander , James

AU - Mullen, Alexander

PY - 2006

Y1 - 2006

N2 - An effective experimental vaccine may fail to become a therapeutic reality for a number of scientific, regulatory or commercial reasons. In this review, we share some of our personal experiences as University-based researchers and provide an account of some of the problems that we have encountered during preliminary scale-up and assessment of an oral influenza vaccine formulation. Many of the problems we have faced have been non-scientific and related to identifying project-funding sources, finding suitable contract manufacturing companies that are GMP compliant, and protecting intellectual property generated from the scientific studies. The review is intended as a practical guide that will allow other researchers to adopt effective strategies to permit the translation of an effective experimental formulation to a viable commercial product.

AB - An effective experimental vaccine may fail to become a therapeutic reality for a number of scientific, regulatory or commercial reasons. In this review, we share some of our personal experiences as University-based researchers and provide an account of some of the problems that we have encountered during preliminary scale-up and assessment of an oral influenza vaccine formulation. Many of the problems we have faced have been non-scientific and related to identifying project-funding sources, finding suitable contract manufacturing companies that are GMP compliant, and protecting intellectual property generated from the scientific studies. The review is intended as a practical guide that will allow other researchers to adopt effective strategies to permit the translation of an effective experimental formulation to a viable commercial product.

KW - vaccines

M3 - Chapter

VL - 38

SP - 65

EP - 68

BT - Methods.

ER -